Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan
Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting
We take a look at 2012's municipal CEF performance, distribution cuts, mergers, and more.
An examination of 10 CEFs with the highest duration risk.
Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)